Skip to content

Study · Animal study (in vivo) · mouse · 2016

11 results

Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.

Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI

Cell metabolism27 Oct 2016Cited by 767 (Europe PMC)

PMID28068222 (opens in a new tab)PMCIDPMC5668137 (opens in a new tab)DOI10.1016/j.cmet.2016.09.013 (opens in a new tab)PepBankPUB-28068222
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, orally administered NMN was rapidly utilized for tissue NAD synthesis.

    In plain wordsIn mice, oral NMN was quickly used to make NAD in tissues.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableUtilization for tissue NAD synthesis
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Orally administered NMN was quickly utilized to synthesize NAD+ in tissues.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In normally aging mice, NMN produced no obvious toxicity or deleterious effects.

    In plain wordsIn normally aging mice, NMN caused no obvious toxicity or harmful effects.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeToxicity or deleterious effects
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Without any obvious toxicity or deleterious effects,
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In normally aging mice, NMN suppressed age-associated body weight gain.

    In plain wordsIn normally aging mice, NMN reduced weight gain associated with age.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseAge-associated body weight gain
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In normally aging mice, NMN enhanced energy metabolism.

    In plain wordsIn normally aging mice, NMN increased energy metabolism.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseEnergy metabolism
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Mitochondrial function · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In normally aging mice, NMN promoted physical activity.

    In plain wordsIn normally aging mice, NMN increased physical activity.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasePhysical activity
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In normally aging mice, NMN improved insulin sensitivity.

    In plain wordsIn normally aging mice, NMN improved insulin sensitivity.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseInsulin sensitivity
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In normally aging mice, NMN improved the plasma lipid profile.

    In plain wordsIn normally aging mice, NMN improved the blood lipid profile.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedPlasma lipid profile
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In normally aging mice, NMN improved eye function.

    In plain wordsIn normally aging mice, NMN improved eye function.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseEye function
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Without any obvious toxicity or deleterious effects, NMN suppressed age-associated body weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and plasma lipid profile, and ameliorated eye function and other pathophysiologies.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In normally aging mice, NMN prevented age-associated gene expression changes in key metabolic organs.

    In plain wordsIn normally aging mice, NMN prevented age-related gene expression changes in key metabolic organs.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableAge-associated gene expression changes
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Aging markers · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with these phenotypes, NMN prevented age-associated gene expression changes in key metabolic organs and enhanced mitochondrial oxidative metabolism and mitonuclear protein imbalance in skeletal muscle.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In normally aging mice, NMN enhanced mitochondrial oxidative metabolism in skeletal muscle.

    In plain wordsIn normally aging mice, NMN increased mitochondrial oxidative metabolism in skeletal muscle.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSkeletal muscle mitochondrial oxidative metabolism
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with these phenotypes, NMN prevented age-associated gene expression changes in key metabolic organs and enhanced mitochondrial oxidative metabolism and mitonuclear protein imbalance in skeletal muscle.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In normally aging mice, NMN enhanced mitonuclear protein imbalance in skeletal muscle.

    In plain wordsIn normally aging mice, NMN increased mitonuclear protein imbalance in skeletal muscle.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSkeletal muscle mitonuclear protein imbalance
    Study

    mousen: not reported in source

    regular chow-fed wild-type C57BL/6N mice during normal aging
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with these phenotypes, NMN prevented age-associated gene expression changes in key metabolic organs and enhanced mitochondrial oxidative metabolism and mitonuclear protein imbalance in skeletal muscle.
    1 context sentence
    Summary · context
    In this study, we conducted a 12-month-long NMN administration to regular chow-fed wild-type C57BL/6N mice during their normal aging.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.